IXICO PLC to support clinical trials for Parkinson's drug

April 4, 2016

The study will see Ixico support the use of novel brain scanning techniques in phase I/II trials

The contract highlighted its growing reputation as leading provider of digital technology in brain health

Brain health company IXICO Plc (LON:IXI) has been awarded a contract by Oxford Biomedica to support clinical trials of a new treatment for Parkinson’s disease.

The study, expected to start by the middle of this year, will see Ixico support the use of novel brain scanning techniques in phase I/II trials to test the experimental Parkinson’s drug, OXB-102.

The group will be involved in the trials for up to five years including follow up trials in the long term, to oversee the use of novel radiopharmaceutical ligands at specialist centres across Europe.

The contract highlighted the company’s growing reputation as a leading provider of digital technology in brain health, said chief executive Professor Derek Hill.

IXICO also announced that it had joined forces with seven global pharmaceutical companies(including AstraZeneca, Biogen and Pfizer) to form the Critical Path for Parkinson’s consortium, formed by Parkinson’s UK.

The aim of the consortium is to standardise clinical trials, share data and bring together researchers to develop safe and effective therapies for the disease.

“It is a privilege to be joining these major global pharmaceutical companies and Parkinson's UK in the Critical Path Institute's CPP consortium and to work together to accelerate progress in developing new therapies,” added Hill.

Shares stood at 39p.

http://www.proactiveinvestors.co.uk/companies/news/124388/ixico-plc-to-support-clinical-trials-for-parkinson-s-drug-124388.html